Definium Therapeutics, Inc.
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
- Ticker
- DFTX
- Trading on
- NASDAQ
- ISIN
- CA24477V1058
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Robert Barrow
- Headquarters
- One World Trade Center, New York, NY, United States, 10007
- Employees
- 105
- Website
- https://definiumtx.com
Metrics
Analyst Insights & forecasts
Based on information from 19 analysts.
Earnings per share (EPS) forecast
| Q4 • 25 | Q1 • 26 | Q2 • 26 | Q3 • 26 | |
|---|---|---|---|---|
| Actual | -$0.45 | -$0.71 | -$1.44 | -$0.46 |
| Expected | -$0.45 | -$0.49 | -$0.55 | -$0.55 |
| Surprise | - | -44.90% | -161.82% | 16.36% |
| Beat | Missed | Missed | Current |
Financial Performance
| Q2 • 26 | Q3 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $0M | $0M | NaN% |
| Net income | $-159M | $-51M | -67.95% |
| Profit margin | -∞% | -∞% | NaN% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a Definium Therapeutics, Inc. share?
Definium Therapeutics, Inc. shares are currently traded for undefined per share.
02How many shares does Definium Therapeutics, Inc. have?
Definium Therapeutics, Inc. currently has 137M shares.
03Does Definium Therapeutics, Inc. pay dividends?
No, Definium Therapeutics, Inc. doesn't pay dividends.
04What is Definium Therapeutics, Inc. 52 week high?
Definium Therapeutics, Inc. 52 week high is $49.70.
05What is Definium Therapeutics, Inc. 52 week low?
Definium Therapeutics, Inc. 52 week low is $10.47.
06What is the 200-day moving average of Definium Therapeutics, Inc.?
Definium Therapeutics, Inc. 200-day moving average is $30.43.
07Who is Definium Therapeutics, Inc. CEO?
The CEO of Definium Therapeutics, Inc. is Robert Barrow.
08How many employees Definium Therapeutics, Inc. has?
Definium Therapeutics, Inc. has 105 employees.
09What is the market cap of Definium Therapeutics, Inc.?
The market cap of Definium Therapeutics, Inc. is $4.13B.
10What is the P/E of Definium Therapeutics, Inc.?
The current P/E of Definium Therapeutics, Inc. is null.
11What is the EPS of Definium Therapeutics, Inc.?
The EPS of Definium Therapeutics, Inc. is -$2.92.
12What is the PEG Ratio of Definium Therapeutics, Inc.?
The PEG Ratio of Definium Therapeutics, Inc. is null.
13What do analysts say about Definium Therapeutics, Inc.?
According to the analysts Definium Therapeutics, Inc. is considered a buy.


